10-Q: Dyadic International Reports Q2 2024 Results: Revenue Declines Amid Strategic Shift Towards Commercialization

Dyadic International's Q2 2024 results reflect a strategic shift towards commercialization, with decreased revenue due to winding down research collaborations, offset by progress in non-pharmaceutical partnerships and a recent capital raise.

Summary

• Dyadic International, Inc., a global biotechnology company, reported its financial results for the second quarter ended June 30, 2024.
• The company's revenue for Q2 2024 was $385,896, a decrease from $793,042 in Q2 2023, primarily due to the completion of several large research collaborations.
• Research and development expenses also decreased to $515,629 in Q2 2024 from $917,552 in the same period last year, reflecting the winding down of the Phase 1 clinical trial for the DYAI-100 COVID-19 vaccine candidate and fewer internal research projects.
• General and administrative expenses increased by 14.6% to $1,607,756 in Q2 2024, driven by higher share-based compensation, legal, business development, and investor relations expenses.
• The net loss for Q2 2024 was $2,045,223, compared to $2,152,960 in Q2 2023.
• On March 8, 2024, Dyadic issued $6.0 million in 8.0% Senior Secured Convertible Promissory Notes to support near-term revenue growth and accelerate commercialization opportunities.
• As of June 30, 2024, Dyadic had $6.1 million in cash and cash equivalents and $4.0 million in investment-grade securities.
• The company is focusing on commercialization opportunities in both pharmaceutical and non-pharmaceutical applications, including a new partnership with Proliant Health and Biologicals for recombinant serum albumin production.

Sentiment

Score: 4

Explanation: The sentiment is mixed, reflecting both challenges and opportunities. While the company reported decreased revenue and a net loss, it also secured funding and made progress in commercialization efforts. The long-term potential of the technology is positive, but near-term financial performance is a concern.

Positives

• New partnership with Proliant Health and Biologicals for recombinant serum albumin production, with potential for significant revenue.
• Progress in developing non-animal dairy enzymes with Inzymes ApS, with a milestone payment expected soon.
• Successful development of DNASE-1, with sampling expected to begin in Q3 2024.
• High titers achieved for recombinant transferrin, with product samples expected in Q4 2024.
• Positive results in third-party testing for recombinant bovine albumin.
• Joint development agreement with a Top 10 global dairy company for food-grade alpha-lactalbumin.
• Sampling of recombinant lactoferrin to several interested parties.
• Development of three enzymes with potential use in multiple industries.
• Positive results in animal studies for the C1 produced H5 A/Astrakhan ferritin nanoparticle vaccine candidate.
• Successful delivery of a C1 produced H1N1 influenza antigen in a collaboration with Massachusetts General Hospital.
• Successful expression of multiple infectious disease antigens and delivery of mAbs in third-party funded programs.
• Recent capital raise of $6.0 million provides funding for near-term operations and commercialization efforts.

Negatives

• Decrease in research and development revenue due to the winding down of several large research collaborations.
• Increase in general and administrative expenses.
• Net loss for the quarter of $2,045,223.
• Continued losses and negative cash flows from operating activities are expected as the company continues development efforts.

Risks

• The company has a history of net losses and expects to incur further losses as it continues development.
• Market and regulatory acceptance of the company's microbial protein production platforms is uncertain.
• The company faces competition from alternative technologies.
• The results of nonclinical studies and clinical trials may not be positive.
• The company may need to raise additional capital, which may not be available on favorable terms.
• Changes in global economic and financial conditions could adversely affect the company.
• The company relies on information technology and is subject to cybersecurity risks.
• The company is dependent on third parties for research and development.
• The company is subject to government regulations and environmental, social, and governance issues.
• The company faces intellectual property risks.

Future Outlook

The company expects its existing cash, cash equivalents, investments, and operating cash flows to be sufficient for at least the next 12 months. They anticipate near-term revenue growth and are accelerating strategic commercialization opportunities in pharmaceutical and non-pharmaceutical applications.

Management Comments

• This private placement funding will support our near-term revenue growth and accelerate our strategic objective of commercialization opportunities for pharmaceutical and non-pharmaceutical applications.

Industry Context

Dyadic's focus on developing its C1-cell and Dapibus protein production platforms aligns with the growing demand for alternative protein sources and efficient biomanufacturing technologies. The company's partnerships in both the pharmaceutical and non-pharmaceutical sectors position it to capitalize on emerging trends in these industries.

Comparison to Industry Standards

• Compared to traditional mammalian cell culture systems like CHO cells, Dyadic's C1-cell platform offers potentially higher productivity and lower production costs. For example, C1 has demonstrated the ability to produce monoclonal antibodies at levels exceeding those typically achieved with CHO cells, as evidenced by collaborations with Janssen and other pharmaceutical companies.
• In the alternative protein space, Dyadic's Dapibus platform is being developed to compete with other microbial expression systems, such as those offered by Perfect Day and The EVERY Company. Dyadic's focus on thermophilic fungi may offer advantages in terms of scalability and cost-effectiveness compared to these competitors.
• Dyadic's progress in developing animal-free serum albumin with Proliant is comparable to efforts by companies like Orbillion Bio and Upside Foods, which are also working on cell culture media components. However, Dyadic's approach using fungal expression may offer cost advantages over mammalian cell-based production methods.
• The company's development of enzymes for various industries positions it alongside companies like Novozymes and DSM, which are major players in the industrial enzyme market. Dyadic's C1 platform may offer advantages in terms of production efficiency and cost for certain enzymes.

Legal Proceedings

• The company is not currently involved in any litigation that it believes could have a materially adverse effect in our financial condition or results of operations.

Related Party Transactions

• $2.0 million of the $6.0 million Convertible Notes were sold to related parties, including immediate family members and family trusts related to Mark Emalfarb, the President and Chief Executive Officer.
• As of June 30, 2024, accrued interest on the Convertible Notes to related parties was $32,000.

Stakeholder Impact

• Shareholders: Potential dilution from the conversion of the Convertible Notes. Long-term value creation depends on the successful commercialization of the company's technology.
• Employees: Continued employment depends on the company's ability to secure funding and achieve commercial success.
• Customers: Potential benefits from the availability of new and improved products developed using Dyadic's technology.
• Suppliers: Continued business depends on the company's ongoing research and development activities.
• Creditors: The Convertible Noteholders have a senior, secured claim on the company's assets.

Next Steps

• Continue the commercialization partnership with Proliant Health and Biologicals for recombinant serum albumin production.
• Begin sampling of DNASE-1 in Q3 2024.
• Provide product samples of recombinant transferrin in Q4 2024.
• Continue development and analysis of recombinant bovine albumin.
• Progress with the development of food-grade alpha-lactalbumin with the Top 10 global dairy company.
• Continue sampling recombinant lactoferrin to interested parties.
• Evaluate the three developed enzymes with interested parties.
• Further develop and evaluate the C1 produced H5 A/Astrakhan recombinant ferritin nanoparticle antigen for poultry and cattle vaccines.
• Continue development of the H5N1 Bird Flu recombinant protein human vaccine candidate.
• Continue the research collaboration with Massachusetts General Hospital on influenza antigens.
• Advance the development of mAbs in third-party funded programs.

Key Dates

Keywords

biotechnology, protein production, gene expression platform, enzymes, vaccines, antibodies, therapeutics, C1-cell, Dapibus, recombinant proteins, animal-free, serum albumin, dairy enzymes, food ingredients, biomanufacturing, pharmaceutical, non-pharmaceutical, research and development, commercialization